| |  Online-Ressource |
|---|
| Verfasst von: | Mahalingam, Devalingam [VerfasserIn]  |
|---|
| | Halama, Niels [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| Titel: | Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors |
|---|
| Titelzusatz: | Final results of first-in-human phase 1 study |
|---|
| Verf.angabe: | D. Mahalingam, M.R. Patel, J.C. Sachdev, L.L. Hart, N. Halama, R.K. Ramanathan, J. Sarantopoulos, X. Liu, S. Yazji, D. Jäger, M. Yoon, G.Ç Manzur, D. Adib, R. Kerschbaumer, A. Tsimberidou |
|---|
| E-Jahr: | 2016 |
|---|
| Jahr: | 16 October 2016 |
|---|
| Fussnoten: | Gesehen am 10.11.2017 |
|---|
| Titel Quelle: | Enthalten in: Annals of oncology |
|---|
| Ort Quelle: | Amsterdam [u.a. : Elsevier, 1990 |
|---|
| Jahr Quelle: | 2016 |
|---|
| Band/Heft Quelle: | 27(2016,Supplement 6) Artikel-Nummer 365PD, 1 Seite |
|---|
| ISSN Quelle: | 1569-8041 |
|---|
| Abstract: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.Background: MIF is a pleiotropic cytokine involved in tumor cell proliferation, angiogenesis, and inflammation. oxMIF is the pathogenic isoform found in tumor and its stroma. Imalumab is a novel recombinant, fully human, monoclonal antibody that targets oxMIF, with antitumor activity.Methods: Dose escalation study (3 + 3 design). Primary endpoint was maximum tolerated dose (MTD). Secondary endpoints were antitumor activity, safety, pharmacokinetics (PK), and pharmacodynamics (PD). Patients (pts), previously treated with other agents, received intravenous (IV) imalumab [28-d cycles; 2 dose schedules]: biweekly in all solid tumors (Q2W); weekly in metastatic colorectal cancer (mCRC), metastatic ovarian cancer (OvCa), and metastatic non-small cell lung cancer (NSCLC) (QW).Results: 50 pts dosed on the trial: 19 (Q2W) in 6 cohorts (1, 3, 10, 25, 37.5, and... |
|---|
| DOI: | doi:10.1093/annonc/mdw368.08 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Kostenfrei: Volltext ; Verlag: http://dx.doi.org/10.1093/annonc/mdw368.08 |
|---|
| | Kostenfrei: Volltext: https://academic.oup.com/annonc/article/27/suppl_6/365PD/2799103 |
|---|
| | DOI: https://doi.org/10.1093/annonc/mdw368.08 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1565245024 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors / Mahalingam, Devalingam [VerfasserIn]; 16 October 2016 (Online-Ressource)
